March 2026 in “Skin Appendage Disorders” This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.
474 citations
,
January 2012 in “Chemistry & biology” This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.
This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.
This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.
11 citations
,
June 2022 in “Frontiers in immunology” This review discusses the challenges in identifying specific hair follicle antigens involved in initiating alopecia areata and highlights the need for further research to understand its etiopathogenesis, reporting no new results.
